Coronary disease risk and prevalence of heart disease in primary care patients with hypertension and renal disease;Riesgo coronario y prevalencia de cardiopatías en pacientes hipertensos con afectación renal en asistencia primaria

Revista Espanola de Cardiologia

Volumn 59, Issue 10, 2006, Pages 1026-1032

  Cosín Aguilar, Juan ^a   Hernándiz Martínez, Amparo ^a   Arístegui Urrestarazu, Rosa ^b   Masramón Morell, Xavier ^c   Aguilar Llopis, Amparo ^a   Rodríguez Padial, Luís ^d   Zamorano Gómez, José L ^e  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b PFIZER INC   (United States)

^c Euroclin   (Spain)

^d HOSPITAL VIRGEN DE LA SALUD   (Spain)

^e HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Cardiovascular risk; Renal damage; Systemic hypertension

Indexed keywords

ADULT; AGED; ANAMNESIS; ANGINA PECTORIS; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY RISK; DIABETES MELLITUS; DISEASE SEVERITY; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; KIDNEY DISEASE; MAJOR CLINICAL STUDY; PERIPHERAL VASCULAR DISEASE; PREVALENCE; PRIMARY MEDICAL CARE; SPAIN;

EID: 34250337528     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1157/13093979     Document Type: Article

References (30)

1. WHO Expert committee. Hypertension control, WHO Tech Rep Ser no. 862. Geneva. World Health Organ Tech Rep Ser. 1996; 862:1-83.
2. Hypertension control. Report of a WHO Expert Committee. J Hypertens. 1999;17:151-83.
3. Parfrey JS, Foley RN. The clinical epidemiology of cardiac disease in chronic renal failure. J Am Soc Nephrol. 1999;10:1606-15.
4. Andrews P. Renal dysfunction as a marker of increased vascular risk. Br J Vasc Dis. 2004;4:152-5.
5. Culleton BF, Larson MG, Wilson PW, Evans JC, Parfrey PS, Levy D, et al. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int. 1999; 56:2214-9.
6. Ruilope LM, Salvetti A, Jamerson K, Hansson L, Warnold I, Wedel H, et al. Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. J Am Soc Nephrol. 2001;12:218-25.
7. Dineen SF, Gerstein HC. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature. Arch Intern Med. 1997;157:1413-8.
8. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med. 1984; 310:356-60.
9. Klausen K, Borch-Johnsen K, Feldt-Rasmussen B, Jensen G, Clausen P, Scharling H, et al. Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation. 2004;110:32-5.
10. Klausen K, Scharling H, Jensen G, Jensen J. New definition of microalbuminuria in hypertensive subjects. Hypertension. 2005; 46:33-7.
11. Wachtell K, Ibsen H, Olsen MH, Borch-Johnsen K, Lindholm LH, Morgensen CE, et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med. 2003;139:901-6.
12. Cosín J, Rodríguez L, Zamorano JL, Arístegui R, Armada B, Hernándiz A, et al. Diferencias de riesgo coronario en pacientes hipertensos de las Comunidades Autónomas. Estudio CORONARIA. Rev Clin Esp. 2004;204:1-12.
13. Cosín J, Hernándiz A, Rodríguez Padial L, Zamorano JL, Arístegui R, Armada B, et al. Valoración del riesgo cardiovascular en grupos de población. Comparación de los sistemas de Score y Framingham en pacientes hipertensos. Rev Clin Esp. 2006;206:182-7.
14. Cosín J, Rodríguez Padial L, Hernándiz A, Arístegui R, Masramón X, Armada B, et al. Riesgo cardiovascular en diabetes mellitus e hipertensión arterial en España. El Estudio CORONARIA. Med Clin (Barc). 2006;127:126-32.
15. Wilson PWF, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factors categories. Circulation. 1998;97:1837-47.
16. Marrugat J, Solanas P, D'Agostino R, Sullivan L, Ordovás J, Cordón F, et al. Estimación del riesgo coronario en España mediante la ecuación de Framingham calibrada. Rev Esp Cardiol. 2003;56:253-61.
17. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24:187-1003.
18. R User's Guide, Version 6, Fourth Edition, Volumes 1 and 2, Cary. North Carolina: SAS Institute, Inc.; 1989.
19. Yuyun MF, Khaw KT, Luben R, Welch A, Bingham S, Day NE, et al. Microalbuminuria independentely predicts all-cause and cardiovascular mortality in a British population: The European Prospective Investigation into Cancer in Norfolk (EPIC-Norfolk) population study. Int J Epidemiol. 2004;33:189-98.
20. Banegas JR, Segura J, Ruilope LM, Luque M, García-Robles R, Campo C, et al. Blood pressure control and physician Management of hypertension in hospital hypertension units in Spain. Hypertension. 2004;43:1338-44.
21. Marín R, Fernández-Vega F, Gorostidi M, Ruilope LM, Praga M, Herrero P, et al. Blood pressure control in patients with chronic renal insufficiency in Spain: a cross-sectional study. Hypertension. 2006;24:395-402.
22. Hillege HL, Janssen WM, Bak AA, Dierks GF, Grobbee DE, Crijns HJ, et al. Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicador of cardiovascular risk factors and cardiovascular morbidity. J Intern Med. 2001;259:519-26.
23. Yuyun MF, Khaw KT, Luben R, Welch A, Bingham S, Day NE, et al. Microalbuminuria, cardiovascular risk factors and cardiovascular morbidity in a British population: the EPIC- Norfolk population-based study. Eur J Cardiovasc Prev Rehabil. 2004;11:207-13.
24. Bonet J, Vila J, Alsina MJ, Ancochea L, Romero R. Prevalencia de microalbuminuria en la población general de un área mediterránea española y su asociación con otros factores de riesgo cardiovascular. Med Clin (Barc). 2001;116: 573-4.
25. Aguirre B. Prevalence of microalbuminuria in a hypertensive population of northern Navarre and its relation to other cardiovascular risk factors. An Sist Sanit Navar. 2004;27:27-36.
26. Valmadrid CT, Klein R, Moss SE, Klein BE. The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus. Arch Intern Med. 2000;160:1093-100.
27. Gerstein HC, Mann JF, Pogue J, Dinneen SF, Halle JP, Hoogwerf B, et al. Prevalence and determinants of microalbuminuria in high-risk diabetic and nondiabetic patients in the Heart Outcomes Prevention Evaluation Study. The HOPE Study Investigators. Diabetes Care. 2000;23 Suppl 2:35-9.
28. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure The JNC 7 Report. JAMA. 2003;289:2519-60.
29. Joint National Committee on Prevention Detection, Evaluation, and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1997; 157:2413-46.
30. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Amer P, et al. The effect of irbesartan on the development of diabetic nefropathy in patientes with type 2 diabetes. N Engl J Med. 2001;345:870-8.